The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.
GLP-1s like the weight-loss drug Wegovy can be made by compounding pharmacies while they're in short supply. Drugmakers argue they no longer are.
Drugs they make aren't generics — rather they buy ingredients from Food and Drug Administration-registered suppliers and prepare finished versions for patients with prescriptions specifically for compounded medicines.Packages of compounded tirzepatide at a compounding pharmacy in Durham, N.C. Only she couldn't. At the time, she could only order one box per day. That meant she could only take care of 30 patients per month — and she had a lot more patients taking compounded tirzepatide than that.in Arlington, Va., says he can't order as much of the Eli Lilly drugs as he needs either. Before the end of the shortage, he said he had"thousands" of patients on compounded products.
She says the company has additionally filed three lawsuits against compounders for improper marketing practices and using an unsafe version of tirzepatide, and she pointed toward an FDA warning letter against a compounding pharmacy in California that recently shut down after a bad inspection.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copiesThe Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make…
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Ozempic, Wegovy move closer to no longer being in shortage, FDA saysAll doses of the weight loss drugs are listed as 'available' by the FDA.
Read more »